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Abstract
For the first time, we publish a special section of four related articles in the online, open-access
journal Child and Adolescent Psychiatry and Mental Health.
Editorial
This special issue is thematically focused on psychophar-
macology, and offers readers the opportunity to examine
recent developments in this area of research as described
from different perspectives.
This section was the result of a conference organized by
the Berlin Brandenburg Academy of Science, together with
the European Academy, and held in Berlin, April 3rd and
4th, 2008. During this conference, which was focused on
ethical, methodological, legal, regulatory, and implemen-
tation issues in designing and conducting research in vul-
nerable populations, speakers from academia, industry,
and government agencies discussed the most recent devel-
opments in pediatric pharmacology research, with special
attention to the conditions determining the necessity and
feasibility of conducting clinical trials in child and adoles-
cent psychiatry.
Benedetto Vitiello (National Institute of Mental Health)
informed about changes in the legal and regulatory frame-
work in the U.S. and implications for clinical trials in
minors. Birka Lehmann form the German Regulatory
Agency informed about the new European framework and
the role of European Medicines Agency (EMEA) and its
committees in implementing the new regulations and
generating more information about the safety and efficacy
of pharmacological treatments in childhood. Philippe
Auby, from Lundbeck Pharmaceuticals, discussed the new
European pediatric research regulations from an industry
perspective. Finally, academic researchers Jacinta Tan and
Michael Kölch discussed ethical preconditions and pitfalls
in child psychiatric pharmacological research in children
and adolescents.
As a chair and discussant at that session I got the impres-
sion that these presentations altogether gave a very good
overview of the current situation and both the advances
and limitations in child psychopharmacotherapy research
in the U.S. and Europe. The coordinated publication of
these reports in CAPMH also offers an opportunity for
readers from other parts of the world to comment on
these issues by submitting letters and rapid communica-
tion articles.
The editorial team is open to suggestions from our reader-
ship and potential authors for other special sections so
that we can invite authors to submit contributions rele-
vant to one general theme under the coordination of a
guest editor. We hope that the addition of thematically
focused special sections to CAPMH will further enhance
the attractiveness of the journal.
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